Uso de paneles de genes en pacientes con alto riesgo de cáncer digestivo hereditario: documento de posicionamiento de la AEG, SEOM, AEGH y consorcio IMPaCT-GENÓMICA

Carball, Sabela; Balaguer, Francesc; Bujanda, Luis; Capellá, Gabriel; González Santiago, Santiago; Jover, Rodrigo; Moreira, Leticia; Pineda, Marta; Ruiz-Ponte, Clara; Sánchez Heras, Ana Beatriz.
Gastroenterol. hepatol. (Ed. impr.) ; 47(3): 293-318, mar. 2024. tab
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-231216

Documentos relacionados

  1. Use of multi-gene panels in patients at high risk of hereditary digestive cancer: position statement of AEG, SEOM, AEGH and IMPaCT-GENÓMICA consortium.
  2. What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?
  3. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis.
  4. Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?
  5. Genetically predicted testosterone and cancers risk in men: a two-sample Mendelian randomization study.
  6. Analysis of Immune Landscape in Pancreatic and Ileal Neuroendocrine Tumours Demonstrates an Immune Cold Tumour Microenvironment.
  7. Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis.
  8. [Hereditary gastric and pancreatic cancer].
  9. Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study.
  10. German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer.